Trending Stock News

Verastem (VSTM) Received Roth Capital’s Coverage; Cintas (CTAS) Sentiment Is 1.04

Among 10 analysts covering Verastem (NASDAQ:VSTM), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Verastem has $17 highest and $1.5000 lowest target. $7.29’s average target is 76.09% above currents $4.14 stock price. Verastem had 26 analyst reports since September 9, 2015 according to SRatingsIntel. Jefferies maintained Verastem, Inc. (NASDAQ:VSTM) rating on Monday, June 26. Jefferies has “Hold” rating and $1.5000 target. The firm has “Mkt Perform” rating given on Tuesday, September 29 by JMP Securities. Oppenheimer maintained Verastem, Inc. (NASDAQ:VSTM) on Monday, June 26 with “Buy” rating. The stock of Verastem, Inc. (NASDAQ:VSTM) has “Strong Buy” rating given on Wednesday, September 9 by Raymond James. The company was maintained on Wednesday, August 16 by Oppenheimer. The rating was downgraded by TH Capital to “Neutral” on Monday, September 28. Cantor Fitzgerald upgraded the stock to “Overweight” rating in Wednesday, September 6 report. The rating was maintained by Oppenheimer on Sunday, June 4 with “Buy”. Mizuho downgraded the stock to “Neutral” rating in Monday, September 28 report. The firm earned “Buy” rating on Monday, September 25 by Cantor Fitzgerald.

Cintas Corporation provides corporate identity uniforms and related business services primarily in North America, Latin America, Europe, and Asia. The company has market cap of $16.74 billion. It operates through Uniform Rental and Facility Services; First Aid and Safety Services; and All Other divisions. It has a 30.88 P/E ratio. The firm rents and services uniforms and other garments, including flame resistant clothing, mats, mops and shop towels, and other ancillary items; and provides restroom cleaning services and supplies, and carpet and tile cleaning services, as well as sells uniforms directly.

Analysts await Cintas Corporation (NASDAQ:CTAS) to report earnings on December, 28. They expect $1.25 earnings per share, up 8.70% or $0.10 from last year’s $1.15 per share. CTAS’s profit will be $132.88M for 31.50 P/E if the $1.25 EPS becomes a reality. After $1.48 actual earnings per share reported by Cintas Corporation for the previous quarter, Wall Street now forecasts -15.54% negative EPS growth.

The stock increased 0.04% or $0.06 during the last trading session, reaching $157.5. About 749,595 shares traded or 27.52% up from the average. Cintas Corporation (CTAS) has risen 32.38% since December 3, 2016 and is uptrending. It has outperformed by 15.68% the S&P500.

Ratings analysis reveals 0 of Cintas’s analysts are positive. Out of 2 Wall Street analysts rating Cintas, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. The lowest target is $123.0 while the high is $130.0. The stock’s average target of $126.50 is -19.68% below today’s ($157.5) share price. CTAS was included in 2 notes of analysts from August 26, 2016. Macquarie Research initiated Cintas Corporation (NASDAQ:CTAS) on Friday, August 26 with “Neutral” rating. As per Tuesday, December 20, the company rating was maintained by Stifel Nicolaus.

Lionstone Capital Management Llc holds 8.85% of its portfolio in Cintas Corporation for 138,000 shares. Junto Capital Management Lp owns 566,680 shares or 6.29% of their US portfolio. Moreover, Jasper Ridge Partners L.P. has 4.36% invested in the company for 644,715 shares. The United Kingdom-based Royal Bank Of Scotland Group Plc has invested 3.93% in the stock. Contravisory Investment Management Inc., a Massachusetts-based fund reported 74,327 shares.

Analysts await Verastem, Inc. (NASDAQ:VSTM) to report earnings on March, 22. They expect $-0.46 EPS, down 43.75% or $0.14 from last year’s $-0.32 per share. After $-0.61 actual EPS reported by Verastem, Inc. for the previous quarter, Wall Street now forecasts -24.59% EPS growth.

Investors sentiment increased to 1.17 in Q2 2017. Its up 0.07, from 1.1 in 2017Q1. It is positive, as 5 investors sold Verastem, Inc. shares while 18 reduced holdings. 13 funds opened positions while 14 raised stakes. 8.68 million shares or 12.61% more from 7.71 million shares in 2017Q1 were reported. Retail Bank Of Ny Mellon has 0% invested in Verastem, Inc. (NASDAQ:VSTM). The California-based Wells Fargo & Mn has invested 0% in Verastem, Inc. (NASDAQ:VSTM). Awm Invest Inc reported 0.02% in Verastem, Inc. (NASDAQ:VSTM). Tower Research Capital Limited Liability (Trc) accumulated 5,027 shares. Raymond James & Assoc invested in 0% or 12,643 shares. Vanguard Gru Incorporated reported 1.14 million shares. Hightower Advisors Lc, Illinois-based fund reported 10,014 shares. Panagora Asset Management owns 28,168 shares for 0% of their portfolio. Connor Clark & Lunn holds 0% or 299,125 shares in its portfolio. Acadian Asset Management Ltd Llc holds 0% or 9,326 shares. Beaumont Fin Partners Lc accumulated 10,000 shares. Alpine Woods Capital Investors Ltd Liability holds 0.01% of its portfolio in Verastem, Inc. (NASDAQ:VSTM) for 50,040 shares. Deer Vii Ltd reported 84.34% in Verastem, Inc. (NASDAQ:VSTM). Moreover, Prelude Cap Mngmt Ltd Liability Co has 0% invested in Verastem, Inc. (NASDAQ:VSTM). First Republic reported 0% of its portfolio in Verastem, Inc. (NASDAQ:VSTM).

Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing drugs for the treatment of cancer. The company has market cap of $167.63 million. The Company’s programs target the focal adhesion kinase and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. It currently has negative earnings. The Company’s lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *